| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pharmaceutical Chemistry [K. P. F., B. V. R.] and Medicine [G. L. W.], Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298
A series of amidoximes was prepared and evaluated for possible antitumor activity against L1210 leukemia. Three of the most active compounds in the L1210 system, formamidoxime, acetamidoxime, and 2-aminoacetamidoxime hydrochloride, were also active against P388 leukemia. Acetamidoxime was marginally active against Lewis lung carcinoma. The active amidoximes showed best activity against L1210 leukemia when given two times daily, 5 hours apart, for 8 days. Most of the amidoximes produced excessive central nervous system stimulation.
1 This work was supported by Grant CA 10572 from the National Cancer Institute and Grant IN-105 from the American Cancer Society.
2 Present address: Pharmaceutical Resources Branch, National Cancer Institute.
3 To whom requests for reprints should be addressed, at Box 292, MCV Station, Richmond, Va. 23298.
Received 5/ 3/77. Accepted 2/ 3/78.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |